ResearcherYamagata UniversityActive in the last 2 years
Yuriko Sasahara
Matched on OpenAlex author ID A5029301944. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 6
- Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. Co-author DOI 10.1002/cam4.71233↗
- Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. Co-author DOI 10.3389/frhs.2024.1275496↗
- Correction: Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. First author DOI 10.1186/s13561-023-00418-x↗
- Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysi… First author DOI 10.1001/jamanetworkopen.2021.45515↗
- Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. First author DOI 10.1186/s13561-022-00413-8↗
- Personalization of chemotherapy for metastatic pancreatic cancer. Co-author DOI 10.4137/ccrep.s14478↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yuki Takumoto · 5 shared papers, 2022–2025 · strength 1.18
- Paper Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. DOI 10.1002/cam4.71233↗
- Paper Correction: Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the … DOI 10.1186/s13561-023-00418-x↗
- Paper Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Sy… DOI 10.1001/jamanetworkopen.2021.45515↗
- Manabu Akazawa · 5 shared papers, 2022–2025 · strength 1.18
- Paper Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. DOI 10.1002/cam4.71233↗
- Paper Correction: Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the … DOI 10.1186/s13561-023-00418-x↗
- Paper Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Sy… DOI 10.1001/jamanetworkopen.2021.45515↗
- Hiroto Narimatsu · 3 shared papers, 2022–2025 · strength 0.74
- Paper Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. DOI 10.1002/cam4.71233↗
- Paper Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Sy… DOI 10.1001/jamanetworkopen.2021.45515↗
- Paper Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. DOI 10.3389/frhs.2024.1275496↗
- Takashi Yoshioka · 2 shared papers, 2014–2024 · strength 0.24
- Kumiko Umemoto · 1 shared paper, 2024 · strength 0.19
- Hiroyuki Takeda · 1 shared paper, 2024 · strength 0.19
- Makoto Ueno · 1 shared paper, 2024 · strength 0.19
- Yu Sunakawa · 1 shared paper, 2024 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.